$ELUT News

Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Elutia Obtains $8M Payment from Boston Scientific; Co. Now Fully Funded into 2029

Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

Elutia (ELUT) Q2 2026 Earnings Call Transcript

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Elutia Inc. 2026 Q2 - Results - Earnings Call Presentation

Elutia Inc. Q2 2026 Earnings Call Summary

Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ...

Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript

Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market

Elutia Q2 2026 Earnings Call Transcript

Elutia Secures Up To $26M Of Additional Capital To Support NXT-41x Clearance And Its First Full Year Of Commercial Launch In 2028

Elutia Q2 EPS $(0.17) Misses $(0.15) Estimate, Sales $2.427M Miss $2.900M Estimate

Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity

Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch